Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
about
Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinomaFrom modules to medicine: How modular domains and their associated networks can enable personalized medicineManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesWhole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Oncogenic Signaling Adaptor ProteinsEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesLoss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growthModels of crk adaptor proteins in cancer.Molecular pathways and therapeutic targets in lung cancerThe quest to overcome resistance to EGFR-targeted therapies in cancer.Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status.Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma.CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.Prospective enterprise-level molecular genotyping of a cohort of cancer patients.Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.Genetic modifiers of EGFR dependence in non-small cell lung cancer.The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian CancerN of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.A functional landscape of resistance to ALK inhibition in lung cancer.Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancerLoss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancerQuality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR.The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKLSomatically mutated ABL1 is an actionable and essential NSCLC survival gene.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerCharacteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patientsAdaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutationOverexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patientsEmerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinomaResisting Resistance: Targeted Therapies in Lung Cancer.In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
P2860
Q24316017-4ADA8416-24FB-46A2-B3D5-86B2CA5D8D9DQ26830811-4888CC6B-9640-4D17-AB5C-52BA146A596AQ26865779-3834D60E-E617-4031-A2E4-210EEAD700DCQ27014117-6F8CD8BB-0C05-4A8F-B2A0-B3CDA1229B80Q27853005-6A15F6DB-0618-447F-B2A8-5441E1E76DBFQ28082384-6887168A-E1DD-4111-82B1-3B370167C308Q28394310-160E1533-F79E-46CF-AB59-928C07CEE1CCQ30009946-D0FD9F62-01F7-405C-B379-350C577D903CQ30009961-59C2511E-D97C-48D8-B3B3-271C17BEEB8CQ33688872-20836CCA-EF90-4D1F-AFE6-93F1C75F2024Q33725976-438B6857-6A7B-423D-A5FF-ECF5AD4DF206Q33733522-80F06A60-26BF-4E68-8E71-3C1B9E74923AQ33743268-C4EDE6CE-506B-43EB-83E3-6A4ED50C41EBQ33808203-0E6999F3-EEC0-4E48-81A7-35EE1768E605Q34409739-3E298517-8A1B-4C4C-9A78-B1D2676F2C4CQ34797680-F9EDA5D2-ABBC-4E25-AC53-03218A2101E0Q34832117-44378969-3ABA-4600-A46A-D6B589A494C2Q35204533-816DC704-A62D-4B0D-A9DA-8574962311F4Q35376207-31C7CBF9-2060-4777-B43B-281B3006A957Q35438912-99295742-8716-429A-B4E4-F8121E955754Q35521281-4A306691-1A09-408B-9C4F-674CF81E9F3FQ36028210-00BCBBD3-A93C-4F26-BA09-0AB9B03E48B9Q36238664-594980DA-CDC7-4343-84DE-F3480A410F9CQ36306149-4CE3DAE1-6466-4627-BF67-F8E0F7E7759CQ36424844-E450CB37-1D63-4DB5-BDC2-6D13E35AFAA1Q36428009-EA79380D-FB8D-4EB2-B3F6-1AEAAA951D91Q36525865-75EFABA7-BDE0-459D-BFD7-30468D41A7D8Q36660669-EF1F7D94-5261-4A97-83A9-0D304C6D5864Q36786792-E85D72A0-9A96-4F57-90B7-8231DCD8A94EQ36801144-77E07721-9669-4A1A-AADF-C8C1078594ACQ36921093-424C6180-EBD4-4346-BF20-6E582C8150BFQ36970403-A9F47C35-F9B4-49CF-8AE1-E8FDBDAF4BA0Q37046462-D2C559E0-0315-4674-8B5C-DF845AE45391Q37159783-93754893-250B-40DC-94B3-17086AC97BE9Q37185801-93F96CF3-8312-4AA1-99B7-3303085292D2Q37249366-CE7D1F41-B8E9-4894-B7D1-0DE12718ECE6Q37301779-6AF03242-B365-473B-A28B-C607260F6284Q37388238-DF1AFC2B-9DCE-41DF-B46F-DC27CA4733AEQ37519684-A26E48A3-ED96-4BD8-AB68-D60E5F185B00Q38021967-464ECEEB-F784-457E-A7D0-46683AC91550
P2860
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Amplification of CRKL induces ...... n non-small cell lung cancers.
@ast
Amplification of CRKL induces ...... n non-small cell lung cancers.
@en
type
label
Amplification of CRKL induces ...... n non-small cell lung cancers.
@ast
Amplification of CRKL induces ...... n non-small cell lung cancers.
@en
prefLabel
Amplification of CRKL induces ...... n non-small cell lung cancers.
@ast
Amplification of CRKL induces ...... n non-small cell lung cancers.
@en
P2093
P2860
P1433
P1476
Amplification of CRKL induces ...... n non-small cell lung cancers.
@en
P2093
Barbara A Weir
David E Root
Hihu Wing Cheung
Jeffrey A Engelman
Jesse S Boehm
Lecia V Sequist
Mohit Butaney
P2860
P304
P356
10.1158/2159-8290.CD-11-0046
P577
2011-10-17T00:00:00Z